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INTRODUCTION
Depression is a very common and significant psychiatric 
complication that affects 30 to 50% of Alzheimer’s disease 
(AD) patients.
1,2 Depression increases the suffering of AD pa-
tients and their families, and compounds consequent disabil-
ity. While other psychiatric symptoms, such as delusion, hal-
lucination, agitation, and apathy, occur mainly in the later 
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stages of AD, depression is common even in the very early 
stage of the disease. Patients with mild cognitive impairment 
(MCI), a preclinical stage of AD, also frequently experience 
depression. The prevalence of depression in MCI has been 
reported to be 16-20%.
3,4 MCI with depression has more than 
a two-fold higher AD conversion rate, compared to MCI 
with no depression.
5,6
A couple of functional neuroimaging studies revealed that 
functional impairment of frontal cortical regions was associ-
ated with depression in AD.
7-9 A previous report by our study 
group has indicated that depressive AD patients have lower 
glucose metabolism in the right superior frontal gyrus than 
non-depressive AD patients.
7 Other [
18F] Fluorodeoxyglu-
cose Positron Emission Tomography (FDG-PET) studies have 
also reported that superior frontal hypometabolism is associ-
ated with depression in AD.
8,9 Hirono et al.
8 reported that de-
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pression was related to hypometabolism in bilateral superior 
frontal and left anterior cingulate cortices. Holthoff et al.
9 re-
ported that reduced glucose metabolism of dorsolateral pre-
frontal regions was associated with depression in AD. However, 
little information is available that relates to the neural sub-
strate of depression in MCI.
The aim of this study was to elucidate the functional neuro-
anatomical substrate of depression in MCI. We first compared 
regional cerebral glucose metabolism between MCI with de-
pression (MCI_D) and MCI with no depression (MCI_ND) 
subjects, considering depression as a syndrome. We further 
investigated the linear relationship between depression se-
verity and regional glucose metabolism in all MCI patients.
METHODS
Subjects
Thirty-six MCI patients including 18 MCI_D and 18 MCI_
ND cases matched for age and gender were recruited from a 
cohort regularly followed at the Dementia & Age-Associated 
Cognitive Decline Clinic at Seoul National University Hospi-
tal. MCI was diagnosed according to current consensus cri-
teria for amnestic MCI.
10 Depression was diagnosed when a 
subject met the major or minor depressive disorder criteria 
of the fourth edition of the Diagnostic Statistical Manual of 
Mental Disorders 4th edition. All MCI individuals had an over-
all clinical dementia rating (CDR)
11 of 0.5. Sixteen cognitively 
normal (CN) elderly individuals were also recruited. All CN 
subjects received a CDR score of 0 and did not meet depression 
criteria.
The following exclusion criteria were applied to all subjects: 
any present serious medical or neurological disorder that could 
affect mental function; any major psychiatric disorders except 
depression, evidence of focal brain lesions on magnetic reso-
nance imaging (MRI) including lacunes and white matter hy-
perintensity lesions of grade 2 or more on the Fazeka scale,
12 
the presence of severe behavioral or communication problems 
that would make a clinical or cerebral imaging of MRI and 
PET examination difficult; ambidextrousness or left-handed-
ness; and the absence of a reliable informant. The Institutional 
Review Board of Seoul National University Hospital, approved 
the study protocol and informed consent was obtained from 
all study subjects and their relatives.
Clinical and neuropsychological assessments
All subjects received a standardized clinical assessment and 
MRI according to the protocol of the Korean version of the 
Consortium to Establish a Registry for Alzheimer’s Disease 
(CERAD) Assessment Packet.
13 
The CERAD neuropsychological battery includes eight neu-
ropsychological tests: Verbal Fluency; 15-item Boston Nam-
ing Test; Mini-Mental State Examination (MMSE); World 
List Memory; Word List Recall; Word List Recognition; Con-
structional Praxis (CP); Constructional Recall, and was ad-
ministered by experienced clinical psychologists. Depression 
severity was assessed using the 17-item Hamilton Rating Scale 
for Depression (HRSD)
14 included in Clinical Assessment of 
Depression in Dementia.
2 A panel consisting of four neuropsy-
chiatrists with expertise in dementia research made clinical 
decisions, including the assignment of clinical diagnosis and 
CDR rating. All clinical assessments were carried out within 4 
weeks of PET examination.
PET imaging
PET studies were performed using an ECAT EXACT 47 
scanner (Siemens-CTI, Knoxville, TN) with an intrinsic reso-
lution of a 5.2 mm full width at half maximum and 47 con-
tiguous transverse plane images with a 3.4 mm thickness for 
a longitudinal field of view of 16.2 cm. Before administering 
FDG, transmission scanning was performed, using 3 germa-
nium-68 rod sources to correct attenuation. Static emission 
scans began 30 minutes after the intravenous injection of 370 
MBq (10 mCi) FDG and were continued for 30 minutes. All 
FDG-PET scans were performed in a dimly lit room with mi-
nimal auditory stimulation during PET scanning, with the sub-
ject in the supine position with their eyes closed to minimize 
confounding effects due to activity. Transaxial images were re-
constructed using a filtered back-projection algorithm employ-
ing a Shepp-Logan filter with a cutoff frequency of 0.3 cycles/
pixel and 128×128×47 matrices of size of 2.1×2.1×3.4 mm.
PET data analysis
Imaging data were analyzed using Statistical Parametric 
Mapping (SPM) 2 (Institute of Neurology, University College 
of London, UK) implemented in the Matlab (Mathworks Inc, 
USA). Before statistical analysis, all images were spatially 
normalized to the Montreal Neurological Institute (MNI, Mc-
Gill University, Montreal, CA, USA) space to correct intersub-
ject anatomical variabilities. An affine transformation was per-
formed to determine the 12 optimal parameters essential for 
registering the brain on the MNI template. Subtle differences 
between transformed images and the template were removed 
by a nonlinear registration method using the weighted sum 
of predefined smooth basis functions used in a discrete cosine 
transformation. Using an in-house Matlab-based program, 
the glucose metabolism value of each voxel was normalized 
for pontine value, which was extracted for each scan, because 
glucose metabolism in the pons tends to be relatively pre-
served in AD.
15 In this program, the volume of interest for the 
pons was predefined in the MNI space and applied to the in-210  Psychiatry Investig 2010;7:208-214
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dividual spatially normalized PET images to measure the 
mean pontine activity. Normalized images were smoothed 
by convolution using an isotropic Gaussian kernel with 16 
mm full width at half maximum to accommodate intersub-
ject differences in gyral and functional anatomies and to in-
crease dataset signal-to noise ratios.
Differences in glucose metabolic values between MCI_D, 
MCI_ND and CN were estimated on a voxel-by-voxel basis us-
ing the t-test. The resulting set of t values constituted the SPM(t) 
map. The SPM(t) was then transformed into a normal distri-
bution to give a SPM(Z).
16 We applied both p value <0.001 
(uncorrected for multiple comparisons) as a significance height 
threshold and 50 voxels as a cluster size threshold to decrease 
the probability of detecting false positives.
17,18 The MNI coor-
dinates of the local maximum of each voxel cluster were au-
tomatically calculated in SPM, and could be transformed to Ta-
lairach and Taurnoux
19 by ‘‘min2tal’’ program (http://imaging.
mrc-cbu.cam.ac.uk/downloads/MNI2tal/).
To further characterize regional glucose metabolic altera-
tions associated with depression, we extracted normalized 
metabolism values at the local maximum of voxel cluster show-
ing a significant difference between MCI_D and MCI_ND in 
voxel-by-voxel analysis using the voxel of interest module of 
SPM. The extracted metabolism values of the region were 
compared between MCI_D, MCI_ND and CN using analysis 
of variance (ANOVA) and post hoc contrasts with Tukey’s me-
thod using Statistical Package for the Social Sciences (SPSS, 
SPSS Inc., Chicago, IL, USA). A partial correlation between de-
pression severity, as measured by HRSD, and the extracted 
metabolism values was also assessed, controlling for age as a 
covariate for all the MCI subjects, using SPSS. In these analy-
ses of extracted values, a p value of <0.05 was applied as the 
threshold of statistical significance.
Other data analysis
The demographic and clinical data from MCI_D, MCI_
ND and CN subjects were compared by ANOVA and post hoc 
contrasts with Tukey’s method for continuous variables and 
χ2 tests for categorical variables using SPSS.
RESULTS
Demographic and clinical characteristics 
of the subjects
Demographic and clinical characteristics for subjects are 
presented in Table 1. MCI_D, MCI_ND and CN did not differ 
in regard to age, gender or education. For all eight neuropsy-
chological tests, including MMSE, there was no significant 
difference between the MCI_D and MCI_ND groups. In con-
trast, both MCI_D and MCI_ND had significantly lower sc-
ores than CN for most of the neuropsychological tests except 
CP. Only MCI_D showed lower CP score than CN, but MCI_
ND did not. MCI_D subjects also had significantly higher 
HRSD scores than did either MCI_ND or CN individuals.
Cerebral glucose metabolic changes associated 
with depression in MCI
Voxel-wise comparison revealed that MCI_D had signifi-
Table 1. Demographic and clinical characteristics of subjects
MCI_D MCI_ND CN p value
No. (F/M) 18 (14/4) 18 (12/6) 16 (9/7) NS
Age (y) 69.4±9.50 69.4±10.1 72.3±5.2 NS
Education (y) 9.7±4.0 8.6±5.0 11.5±4.1 NS
HRSD score 12±4.0 2.6±3.0 0.63±1.5 <0.05*†
Neuropsychiatric tests
Word fluency 39.9±11.2 44.2±7.80 058.4±11.1 <0.05†‡
15-item Boston Naming 44.2±12.5 46.9±9.90 57.6±6.7 <0.05†‡
Mini-Mental State 22.7±22.3 33.1±14.5 52.3±7.5 <0.05†‡
Word List Memory 40.6±13.4 40.6±10.2 61.4±8.9 <0.05†‡
Constructional Praxis 46.3±13.2 49.3±10.0 55.6±4.3 <0.05†
Word List Recall 41.3±10.2 35.3±10.2 58.0±6.2 <0.05†‡
Word List Recognition 40.5±14.6 35.6±16.6 52.8±7.1 <0.05†‡
Constructional Recall 36.3±9.60 41.4±8.90 54.0±7.2 <0.05†‡
Data are presented as mean±SD. All neuropsychological test scores are age, education and gender-specific norm corrected t-tests. Group 
comparisons are by analysis of variance. Post hoc comparisons of significant group differences. *MCI_D vs. MCI_ND, †MCI_D vs. CN, 
‡MCI_ND vs. CN. HRSD: Hamilton Rating Scale for Depression, MCI_D: mild cognitive impairment with depression, MCI_ND: mild cog-
nitive impairment with no depression, CN: cognitively normalHS Lee et al. 
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cantly lower glucose metabolism in the right superior frontal 
region [Brodmann’s area (BA) 6] than MCI_ND (Table 2, Fig-
ure 1). In contrast, there was no brain region where MCI_D 
showed increased glucose metabolism compared with MCI_
ND. Voxel-based analysis also showed that MCI_D had sig-
nificantly lower glucose metabolism in the bilateral precune-
us (BA 31 and BA 7), right superior parietal gyrus (BA 6), left 
postcentral gyrus (BA 47), left fusiform gyrus (BA 39), and left 
parahippocampal gyrus (BA 6) than CN. MCI_ND also showed 
marginally significant hypometabolism in the right precune-
us (BA 31), compared with CN (Table 2).
To characterize further glucose metabolic alteration asso-
ciated with depression on the right superior frontal region, we 
extracted normalized metabolism values at the local maxi-
mum of voxel cluster showing a significant difference between 
MCI_D and MCI_ND groups using the voxel of interest mo-
dule of SPM. There was a significant between-group differ-
ence in the extracted regional metabolism value between MCI_
D, MCI_ND, and CN groups (F=7.87, df=2; p<0.005). As 
shown in Figure 2, both MCI_ND and CN groups had signifi-
cantly higher glucose metabolism than MCI_D, while there 
was no significant difference between MCI_ND and CN groups. 
There was also a significant correlation between HRSD scores 
and the extracted metabolism values in overall MCI subjects 
(partial correlation coefficient =-0.418; p=0.012)(Figure 3).
Table 2. Brain areas showing significant hypometabolism in group comparisons
Brain region BA
Coordinates (mm)
Voxels (N) Z score
p value
(uncorrected) X Y Z
MCI_D vs. MCI_ND
Right superior frontal gyrus 06 30.0 -8.0 -69.0 29 3.35 <0.001
MCI_D vs. CN
Right precuneus 31 14.0 -53.0 32.0 1,198 4.02 <0.001
Left precuneus 07 -24.0 -68.0 35.0 1,108 3.65 <0.001
Right superior parietal gyrus 06 65.0 3.0 15.0 645 3.49 <0.001
Left postcentral gyrus 47 50.0 48.0 -10.0 679 3.43 <0.001
Left fusiform gyrus 39 50.0 -61.0 18.0 516 3.38 <0.001
Left parahippocampal gyrus 06 26.0 -14.0 69.0 126 3.32 <0.001
MCI_ND vs. CN
Right precuneus 31 16.0 -57.0 34.0 29 3.18 <0.001
Coordinates (x, y and z) refer to a standard stereotactical space.
19 Each coordinate indicate the voxel location with the highest z score within 
each brain region. MCI_D: mild cognitive impairment with depression, MCI_ND: mild cognitive impairment with no depression, CN: cog-
nitively normal
Figure 1. Statistical parametric maps sh-
owing decreased glucose metabolism 
in mild cognitive impairment (MCI) with de-
pression compared with MCI without de-
pression at p < 0.001 (uncorrected).
80
60
40
20
0
MCI_ND MCI_D CN
R
e
l
a
t
i
v
e
 
m
e
t
a
b
o
l
i
s
m
 
o
f
 
R
S
F
G
Figure 2. Group comparisons of glucose metabolism in the right su-
perior frontal region. Error bars indicate SDs. *p<0.005 by Tukey’s 
post hoc group comparison. RSFG: right superior frontal gyrus,   
MCI_D: mild cognitive impairment with depression, MCI_ND: mild 
cognitive impairment with no depression, CN: cognitively normal.
*
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DISCUSSION
Through a voxel-based approach, we found that MCI_D had 
significantly lower glucose metabolism in the right superior 
frontal region than MCI_ND. Furthermore, depression sever-
ity as measured by HRSD showed a significant negative cor-
relation with glucose metabolism in the same brain region. To 
the best of our knowledge, this is the first study that reveals the 
functional neuro-anatomical substrate associated with depres-
sion in MCI.
The finding that reduced frontal glucose metabolism is re-
lated to depression in MCI is generally in line with the results 
of previous neuro-imaging studies on secondary depression, 
as well as primary depression, although the exact locations re-
lating to depression within the frontal cortex vary among the 
studies.
7-9,20-24 More specifically, focusing on AD process-relat-
ed depression, a previous FDG-PET study by our group
7 in-
dicated that depression in AD is associated with hypometab-
olism in the right superior frontal region (BA 6), the very re-
gion related to depressive MCI in the current study. Other 
FDG-PET studies
8,9 also demonstrated that depression score 
correlates significantly with glucose hypometabolism in the 
bilateral superior frontal or dorsolateral prefrontal cortices. 
In one single photon emission computerized tomography study, 
depressed AD patients showed lower perfusion in the bilat-
eral superior frontal gyrus than non-depressed AD patients.
24 
These converging results from both our MCI and previous AD 
studies on depression correspond well with the fact that am-
nestic MCI is a preclinical or high risk state of AD.
25-27
Although BA 6 has long been recognized as a premotor or 
high-order motor area, this does not necessarily indicate that 
motor system deficit has a close relationship with depression 
in MCI or early AD process.
7 The rostral parts of BA 6, where 
depression-related hypometabolism was observed in the cur-
rent study, are closely interconnected with the prefrontal cor-
tex rather than the primary motor cortex, while the caudal 
parts of BA 6 have a close relationship with the primary mo-
tor cortex.
7,28  Therefore, it seems more likely that the deficit 
of rostral BA 6 in depressive MCI is related to prefrontal dys-
function than to motor system dysfunction. A recent report 
showed that loss of motivated behavior including work, ac-
tivities, appetite and libido in primary depression correlated 
with decreased glucose metabolism in BA 6.
29 
While MCI_D showed superior frontal hypometabolism 
compared with MCI_ND, voxel-based analysis did not reveal 
any metabolic differences in the same region between MCI_
D and CN or between MCI_ND and CN. The lack of a signifi-
cant finding in this regard is probably related to the threshold 
for statistical significance used in voxel-based analysis. Our 
study applied a relatively strict threshold (p<0.001) to reduce 
the possibility of false positive results (alpha error) due to mul-
tiple comparisons. However, this increases the possibility of 
false negative results (beta error). When we re-analyzed with a 
less strict statistical threshold (p<0.005, by ANOVA with Tu-
key’s post hoc comparison) focusing on the right superior fron-
tal region, MCI_D patients showed significantly lower me-
tabolism than either CN or MCI_ND individuals.
Both MCI_D and MCI_ND showed lower glucose metab-
olism in the precuneus than CN. This finding corresponds 
with the results of earlier studies, which reported glucose hy-
pometabolism in the medial parietal region including the pre-
cuneus and posterior cingulate cortex in MCI and very early 
AD.
30-34 It also lends credence to the assumption that the MCI 
subjects recruited in our study represent preclinical AD pa-
tients. In addition, compared with CN, MCI_D patients show-
ed hypometabolism in parieto-temporal regions other than 
the precuneus, but MCI_ND patients did not. This finding, 
together with depression-associated frontal hypometabolism 
in MCI detected through direct comparison, might suggest that 
MCI_D have a more diffuse deposition of AD related pathol-
ogies than MCI_ND, although there were no significant differ-
ences in apparent neuropsychological test performances be-
tween MCI_D and MCI_ND (Table 1). Compatible with this, 
previous studies reported that parieto-temporal hypometab-
olism found in MCI patients was associated with increased 
progression to clinical AD,
35-37 and that the presence of depres-
sion in MCI patients increased the risk for conversion to clin-
ical AD.
5,6 Also, there were a couple of reports that amyloid 
beta deposition, a major component of neuritic plaque, was 
associated with late-life depression.
38,39
There are some possible limitations to the present study. 
First, the relatively small sample size and potential selection 
bias related to subject recruitment from a tertiary hospital co-
hort mean caution is required about generalizing from the re-
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Figure 3. Illustration of the significant correlation obtained be-
tween depression severity (Hamilton Rating Scale for Depression 
scores) and glucose metabolism in the right superior frontal gyrus 
in mild cognitive impairment subjects overall. HRSD: Hamilton 
Rating Scale for Depression.HS Lee et al. 
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sults. In particular, low statistical power due to small sample 
size may make it difficult to detect other regional brain sub-
strates less strongly associated with depression in MCI than 
the right superior frontal region. Second, we did not apply par-
tial volume effect (PVE) correction to the PET data and, there-
fore, brain hypometabolism in MCI might be overestimated, 
compared with CN. However, given that overall brain atro-
phy is less prominent in MCI, and that PVE due to brain at-
rophy does not alter the general pattern of differences of me-
tabolism in AD, especially in mild cases,
40 it is not likely to affect 
our results to any great degree.
In conclusion, our finding of frontal hypometabolism as-
sociated with depression in MCI corresponds with previous 
reports on depression in AD and suggests that the functional 
disruption of the frontal region is associated with depression 
in preclinical AD, as well as in clinically evident AD. When com-
bined with previous observations on primary and secondary 
depression, these results suggest that frontal dysfunction is 
probably associated with depression, regardless of the etiology.
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